A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms GALACTIC-HF
  • Sponsors Amgen
  • Most Recent Events

    • 19 Sep 2017 According to a Cytokinetics media release, first patient ij Japan has been dosed.
    • 08 Jun 2017 Planned initiation date changed from 1 Jan 2017 to 6 Jan 2017.
    • 20 Jan 2017 Planned End Date changed from 1 Mar 2021 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top